Plus, news about Crinetics, Compass Pathways, Amylyx Pharmaceuticals, Mersana Therapeutics, Guggenheim Partners, Sciwind Biosciences, 4D Molecular Therapeutics, Barinthus Bio, Y-mAbs Therapeutics and Meiji Seika Pharma
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Four new biotechs launched Friday with megarounds and in-licensed treatment candidates, giving the industry an $800 million boost ahead of the year’s biggest dealmaking event
Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, will step down, the agency confirmed Friday. An email was sent to employees
Two biotechs emerged on Friday with assets from Keymed Biosciences, extending a proliferating trend of Western investors propping up new companies to further develop assets
As the new Congress and a new administration start up, the fate of FDA-issued regulations on laboratory-developed tests (LDTs) is one of many issues that
FDA advisors largely supported the regulatory approval of condoliase for nerve pain associated with lumbar disc herniation (LDH) if it can be targeted to the
Nearly 5,000 healthcare workers from Providence Health began a strike Friday morning, picketing all eight Providence hospitals in Oregon, after months of contract negotiations between
Repetitive transcranial magnetic stimulation (rTMS) added to tai chi chuan exercise improved sleep and cognition in older adults who had both sleep disorders and mild
Survivors of childhood cancer face challenges from bone mineral density (BMD) deficits due to treatment exposures and other factors, some of which may be modifiable,